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Abstract
Background: To investigate the ameliorating effect of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on blood
glucose control in patients with type 2 diabetes mellitus who were previously untreated with or who have a
poor responsive to existing antidiabetic drugs.
Methods: Sitagliptin (50 mg/day) was added on to the pre-existing therapy for type 2 diabetes and changes
in the glycated hemoglobin (HbA1c) level after 3 months of treatment were compared with the baseline and
performed exploratory analysis.
Results: HbA1c levels were significantly decreased after 1 month of treatment compared to baseline, with a
mean change in HbA1c level from baseline of −0.73% (range, −0.80 to −0.67) in the entire study population
at 3 months. Patients who received a medium dose of glimepiride showed the least improvement in HbA1c
levels. The percentage of patients who achieved an HbA1c level of <7.0% significantly increased after
1 month of treatment, reaching 53.1% at 3 months. The percentage of patients who achieved a fasting blood
glucose level of <130 mg/dL significantly increased after 1 month of treatment, reaching 50.9% at 3 months.
Conclusions: Sitagliptin improved the HbA1c level and rate of achieving the target control levels in patients
with type 2 diabetes mellitus who were previously untreated with, or poorly responsive to, existing
antidiabetic drugs. Thus, sitagliptin is expected to be useful in this patient group. However, the additional
administration of sitagliptin in patients treated with medium-dose glimepiride only slightly improved blood
glucose control when corrected for baseline HbA1c level.
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Background
The 2012 National Health and Nutrition Survey con-
ducted by the Ministry of Health, Labour and Welfare of
Japan (MHLW) estimated that approximately 20.5 mil-
lion people were strongly suspected of having diabetes
mellitus; these patients are considered the at-risk group
of individuals in whom diabetes mellitus cannot be ruled
out [1]. An increasing amount of patients strongly sus-
pected of having diabetes mellitus are currently being
treated with existing antidiabetic drugs (men, 65.9% and
women, 64.3%) [1]. However, existing antidiabetic drugs
have various drawbacks, including insufficient efficacy,
short-lasting effect [2], body weight increase and incon-
venient administration. Thus, new drugs that have a dif-
ferent mechanism of action and that show improved
efficacy, safety and tolerability are required.
Dipeptidyl peptidase-4 (DPP-4) inhibitors exhibit anti-
diabetic effects by stimulating insulin secretion through
highly selective inhibition of DPP-4, an enzyme that in-
activates incretins such as glucagon-like peptide 1 and
gastric inhibitory polypeptide via a mechanism different
from that of conventional hypoglycemic drugs. Many re-
ports have demonstrated the superior efficacy and safety
of DPP-4 inhibitors [3–5], among which sitagliptin was
the first to gain approval in Japan in 2009. Many reports
of sitagliptin had published, but we have examined the
additional effect of sitagliptin in 7 pre-existing therapy
groups. Treatment of these patients often includes other
antidiabetic medications because they often have diverse
complications. The objective of this study is to investi-
gate the ameliorating effect of sitagliptin on blood glu-
cose control in patients with type 2 diabetes mellitus,
who were previously untreated with, or who had a poor
responsive to, existing antidiabetic drugs.
Methods
Study design
This open-label, central registration, multi-center, pro-
spective observational study was conducted at the Tokyo
Women’s Medical University Hospital and 69 collaborat-
ing institutions in Japan. Patients were enrolled from 1
January 2011 to 30 June 2013, and followed up until 30
June 2014. This study was conducted with the approval
of the ethic committee of the Tokyo Women’s Medical
University (UMIN000019154).
Study subjects
The study subjects were male or female, 20 years of age
or older, and outpatients with type 2 diabetes mellitus
and inadequately controlled blood glucose levels (a gly-
cated hemoglobin (HbA1c) level of ≥6.9% (52 mmol/
mol) or a fasting blood glucose level of ≥ 130 mg/dL [6]
during the observation period) after at least 1 month of
receiving diet/exercise therapy or/and oral antidiabetic
drug therapy.
The participants were treated with diet and exercise
therapy, low-dose glimepiride (0.5–1 mg), medium-dose
glimepiride (1.5–2 mg), biguanides, thiazolidines, α-
glucosidase inhibitors or two or more of these drugs in
combination during the observation period. And pa-
tients treated with more than 2 mg of glimepiride or
other SUs were excluded from the study.
The all patients provided written informed consent be-
fore participation.
Patients who met any of the following criteria were ex-
cluded from the study: (i) history of severe ketosis, dia-
betic coma or pre-coma within the past 6 months; (ii)
severe infection before or after surgical treatment, or
serious external injury; (iii) pregnancy, possible preg-
nancy or lactation; (iv) moderate renal impairment
(serum creatinine level ≥1.5 mg/dL in men and ≥1.3 mg/
dL in women); (v) patients on insulin therapy; (vi) pa-
tients on treatment with rapid-acting insulin secreta-
gogues; (vii) history of allergy to the ingredients of the
study drug; and (viii) a medical reason that makes the
patient unsuitable for participation in the study as
judged by the investigator.
Treatment with (v) and/or (vi) were not covered by
national health insurance at the time of setting the study
protocol.
Treatments
The pre-existing therapy for type 2 diabetes were not
changed during the observation period and entire study
period (for the first 3 months after add-on sitagliptin).
Thereafter, sitagliptin (50 mg) was administered once
daily as a first-line treatment (single-drug therapy) or as
an additional treatment (combination therapy; Fig. 1).
During the 3-month period from the initiation of sita-
gliptin treatment (baseline), administration of sitagliptin
was continued without the addition of any other drugs
or dose increases. At 3 months, the sitagliptin dose was
increased from 50 to 100 mg/day and other antidiabetic
drugs were added, changed or discontinued at the inves-
tigator’s discretion. No restrictions were imposed on the
use of drugs for treating concurrent diseases, but dose
changes or the addition of new drugs was avoided when-
ever possible during the study period.
Evaluation
All end points were defined in the study protocol prior
to implementation of the study. The primary end point
was the change in HbA1c level at 3 months from base-
line. The secondary end points were as follows: the per-
centage of patients who achieved a normal HbA1c level
(<7.0%, 53 mmol/mol [6]) and the percentage of patients
who achieved a normal fasting blood glucose level
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(<130 mg/dL) at 1, 3 and 12 months after the start of
treatment; changes in HbA1c from baseline at 1 and
12 months after starting treatment; and fasting blood
glucose level, homeostatic model of assessment-β index
and blood lipid levels (low-density lipoprotein choles-
terol [LDL-C], triglycerides [TG], and high-density lipo-
protein cholesterol [HDL-C]) at 3 and 12 months after
starting treatment.
In addition, the HbA1c level at 3 months of treatment
and the change in HbA1c level from baseline were cal-
culated for each patient group classified according to the
concomitant drug used. The approximate linear correl-
ation between the baseline HbA1c level and the change
in HbA1c level after 3 months of treatment was exam-
ined statistically using an exploratory approach. Multiple
linear regression analysis was performed using the devi-
ation from the correlation line as the dependent variable.
Safety assessments included the incidence of adverse
drug reactions and hypoglycemia during the study
period.
At the start of the study in 2011, HbA1c values were
expressed in The Japan Diabetes Society levels, the
standard system in Japan, but were changed to National
Glycohemoglobin Standardization Program (NGSP) sys-
tem values at the end of the study in accordance with
the “Report of the Committee on the Classification and
Diagnostic Criteria of Diabetes Mellitus (Revision for
International Harmonization),” issued by The Japan Dia-
betes Society [7]. Pursuant to the above change, the
lower limit of inadequate blood glucose control was also
changed. Therefore, patients with an HbA1c level of
≥6.9% (52 mmol/mol) were enrolled at the start of the
study, but at the data analysis stage, the percentage of
patients who achieved the target HbA1c level of ≥7.0%
(53 mmol/mol) or <7.0% (53 mmol/mol) was calculated.
Statistical analysis
Data analysis was performed using IBM SPSS Statistics
22.0 for Windows (IBM Japan, Ltd.). Observed values
were analyzed using a paired t test, while a between-
group comparison of changes was performed using ana-
lysis of variance. The chi-square test was used to analyze
the percentage of patients who achieved the HbA1c tar-
get level, and correlation was evaluated using Pearson’s
test. The factors that affect the fasting blood glucose-
lowering effect were evaluated using simple and multiple
regression analyses, with the significance level set at 5%
(two-sided). Demographic characteristics are presented
as the mean ± standard deviation (SD), and the observed
values are presented as the mean ± standard error (SE).
Changes are presented as the mean (95% confidence
interval [CI]).
Results
Figure 2 shows the flow diagram of the patient enroll-
ment in the study. Of the 779 patients with T2DM en-
rolled, 651 were included in the Efficacy analysis (Diet/
exercise therapy, 189; Low-dose glimepiride, 72; Medium-
dose glimepiride, 50; Biguanide, 99; Thiazolidine, 38; α-GI,
18; Combination therapy, 185). Table 1 shows the baseline
Fig. 1 Study design. *1 Criteria for inadequate blood glucose control: HbA1c level ≥6.9% (52 mmol/mol) or fasting blood glucose level ≥130 mg/
dL. *2 Specific investigational tests (optional): GA, 1.5AG, C-peptide, proinsulin-to-insulin ratio
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demographics of the 651 patients who were classified
according to the concomitant drug used and evalu-
ated to determine treatment efficacy. Past or concurrent
illnesses in the entire study population are also presented
in Table 1. There were 22 (3.4%) participants at 3 months
and 37 (5.7%) participants at 12 months reported as poor
adherence of sitagliptin.
The HbA1c level significantly decreased after one
month of treatment compared to baseline (p < 0.05), and
this reduction was maintained throughout 12 months of
treatment (Additional flile 1: Figure S1). The change
(95% CI) in HbA1c level from baseline in the entire pa-
tient population was −0.73% (−0.80 to −0.67) at 3 months
of treatment. There was no significant difference in the
change in HbA1c level between the patient groups
treated with different concomitant drugs (Fig. 3 and
Additional file 3).
The HbA1c level normalization rate, expressed as the
percentage of patients who achieved an HbA1c level of
<7.0% (53 mmol/mol), significantly increased at 1 month
compared to baseline (p < 0.05), reaching an increase in
53.1% at 3 months (Additional flile 2: Figure S2). The
fasting blood glucose normalization rate, calculated as
the percentage of patients who achieved a fasting blood
glucose level of <130 mg/dL, significantly increased at
1 month compared to baseline (p < 0.05), reaching an in-
crease of 50.9% at 3 months (S2). We enrolled patients
who meet the criteria of a glycated hemoglobin (HbA1c)
level of ≥6.9% (52 mmol/mol) or a fasting blood glucose
level of ≥ 130 mg/dL [6] during the observation period.
Consequently, this study include patients who were
achieved the HbA1c goal/or the fasting blood glucose
goal at baseline.
Table 2 shows the changes (95% CI) in most labora-
tory parameters at 3 and 12 months after the start of
treatment compared with baseline. Improvement was
observed in many of the diabetes mellitus-related
parameters.
The factors that affect the blood glucose-lowering effect
of sitagliptin were also investigated. A negative correlation
(R = −0.528, p < 0.05) was observed between the baseline
HbA1c level and the change in HbA1c level from baseline
to 3 months (S3). Related factors other than baseline
HbA1c level were also investigated. For this purpose, the
approximate linear correlation between the baseline
HbA1c level and that at 3 months of treatment was calcu-
lated. A single regression analysis was performed using
the deviation from the correlation line as the dependent
variable. The results indicate that age, body mass index,
mean blood pressure and concomitant administration of
medium-dose glimepiride significantly affected sitagliptin
efficacy (Table 3). Using the factors that showed a signifi-
cant effect, multiple regression analysis was performed on
the deviation from the approximate linear correlation.
Only medium-dose glimepiride significantly affected sita-
gliptin efficacy (p = 0.017; Table 3).
Table 4 shows the changes in anti-diabetic medication
during the study and 86 patients were increased the dose
of sitagliptin after the 3 months of follow-up visits.
Adverse events observed in the 711 safety-evaluable pa-
tients included clinical symptoms in 37 patients and la-
boratory abnormalities in 18 patients (Table 5). 19 out of
55 patients discontinued administration of sitagliptin be-
cause of the adverse event. Four of these events, anemia
(sitagliptin single-drug group), hypoglycemia (multiple-
drug co-administration group, low-dose glimepiride
Fig. 2 Patient enrollment flow diagram
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Table 1 Patient demographic characteristics
Group Parameter (Sitagliptin only) +Sitagliptin (combination therapy)
Overall Diet/exercise therapy Low-dose glimepiride (0.5–1.0 mg) Medium-dose glimepiride
(1.5–2.0 mg)
Biguanide Thiazolidine α-GI Coadministration of
two or more drugs
n 651 189 72 50 99 38 18 185
Age (y) 63.8 ± 11.8 64.6 ± 12.7 68.1 ± 11.1 65.3 ± 11.2 59.3 ± 11.4 64.3 ± 12.2 63.9 ± 11.7 63.2 ± 10.8
Sex (male %) 434 (66.7) 121 (64.0) 44 (61.1) 37 (74.0) 72 (72.7) 27 (71.1) 13 (72.2) 120 (64.9)
BMI (kg/m2) 25.2 ± 4.2 24.5 ± 4.1 24.3 ± 4.0 24.5 ± 3.5 25.8 ± 3.6 26.4 ± 7.1 25.9 ± 3.9 25.7 ± 4.1
Abdominal circumference (cm) 88.3 ± 11.1 87.3 ± 10.7 88.7 ± 10.7 85.1 ± 8.2 88.9 ± 9.0 92.9 ± 21.4 92.4 ± 7.2 87.9 ± 10.1
Disease duration (y) 8.8 ± 6.7 6.2 ± 5.7 8.2 ± 6.4 10.2 ± 8.1 9.4 ± 6.8 10.5 ± 7.1 8.7 ± 5.7 10.5 ± 6.5
Smoking habit (%) 143 (22.7) 32 (17.4) 14 (20.3) 16 (34.0) 26 (27.1) 5 (13.5) 4 (22.2) 46 (25.6)
Drinking habit (%) 301 (48.1) 79 (42.5) 31 (47.0) 33 (68.8) 51 (53.1) 19 (52.8) 10 (55.6) 78 (44.3)
HbA1c (%) 7.86 ± 1.07 7.67 ± 1.09 7.74 ± 0.86 8.23 ± 1.31 8.05 ± 1.10 7.64 ± 0.74 7.26 ± 0.76 8.00 ± 1.04
Converted mean HbA1c
(mmol/mol)
62 60 61 66 64 60 56 64
Fasting blood glucose (mg/dL) 159.2 ± 41.5 152.7 ± 43.5 156.6 ± 35.4 166.5 ± 38.7 173.5 ± 48.1 154.1 ± 38.3 146.0 ± 43.3 158.9 ± 36.5
HOMA-IR 2.83 ± 1.80 2.36 ± 1.45 2.70 ± 1.69 2.97 ± 1.92 3.34 ± 1.72 2.68 ± 2.03 2.69 ± 1.75 3.01 ± 2.03
HOMA-β (%) 32.1 ± 27.1 32.6 ± 33.9 29.4 ± 20.1 33.4 ± 25.7 31.5 ± 22.7 29.1 ± 21.3 36.0 ± 35.2 33.0 ± 25.3
C-Peptide (ng/mL) 2.10 ± 0.89 2.10 ± 0.90 2.36 ± 1.64 2.08 ± 0.58 2.14 ± 0.74 1.97 ± 0.78 2.00 ± 0.74 2.05 ± 0.96
SBP (mmHg) 130.9 ± 14.9 128.9 ± 16.1 134.0 ± 13.4 131.8 ± 11.4 131.0 ± 16.5 131.6 ± 16.3 130.5 ± 13.4 131.4 ± 13.8
DBP (mmHg) 76.5 ± 10.5 75.7 ± 9.7 76.5 ± 9.5 77.3 ± 10.3 79.6 ± 11.9 76.8 ± 11.4 79.7 ± 12.0 75.1 ± 10.2
Hypertension 393 (60.4) 107 (56.6) 46 (63.9) 29 (58) 60 (60.6) 24 (63.2) 13 (72.2) 114 (61.6)
Dyslipidemia 417 (64.1) 102 (54) 41 (56.9) 34 (68) 72 (72.7) 25 (65.8) 12 (66.7) 131 (70.8)
Hyperuricemia 65 (10) 17 (9) 4 (5.6) 2 (4) 13 (13.1) 5 (13.2) 7 (38.9) 17 (9.2)
Retinopathy 48 (7.4) 7 (3.7) 3 (4.2) 2 (4) 18 (18.2) 1 (2.6) 3 (16.7) 14 (7.6)
Arteriosclerosis obliterans 55 (8.4) 8 (4.2) 2 (2.8) 2 (4) 25 (25.3) 2 (5.3) 2 (11.1) 14 (7.6)
Atrial fibrillation 16 (2.5) 5 (2.6) 2 (2.8) 2 (4) 2 (2) 1 (2.6) 0 (0) 4 (2.2)
Renal disease 49 (7.5) 5 (2.6) 2 (2.8) 2 (4) 16 (16.2) 3 (7.9) 4 (22.2) 17 (9.2)
Hepatic disease 56 (8.6) 15 (7.9) 3 (4.2) 4 (8) 14 (14.1) 4 (10.5) 3 (16.7) 13 (7)
Myocardial infarction 18 (2.8) 5 (2.6) 2 (2.8) 1 (2) 3 (3) 0 (0) 2 (11.1) 5 (2.7)
Cerebral stroke 45 (6.9) 8 (4.2) 4 (5.6) 3 (6) 6 (6.1) 3 (7.9) 4 (22.2) 17 (9.2)
Angina pectoris 27 (4.1) 9 (4.8) 2 (2.8) 3 (6) 6 (6.1) 1 (2.6) 1 (5.6) 5 (2.7)
Cardiac failure 11 (1.7) 3 (1.6) 3 (4.2) 1 (2) 1 (1) 0 (0) 0 (0) 3 (1.6)
Data presented as n (%) or mean ± SD
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co-administration group), urticaria (multiple-drug co-
administration group), were judged by the investigator to
be causally related to the study drug. The incidence of an
adverse drug reaction was 0.56%. Hypoglycemia occurred
in three patients (0.42%), but all the cases were mild. They
were judged to be causally related to the study drug in
one patient each in the multiple drug co-administration
and low-dose glimepiride groups, and as possibly causally
related to the study drug in one patient in the sitagliptin
single-drug group.
Discussion
In the present study, the overall sitagliptin-induced de-
crease (95% CI) in HbA1c level from baseline was
−0.73% (range, −0.80 to −0.67) at 3 months. In many
studies, sitagliptin reportedly improved HbA1c and fast-
ing blood glucose levels both as a single-drug therapy
[3, 8–10] and as a combination therapy with other antidi-
abetic drugs [4, 5, 11]. In our study, we excluded patients
undergoing insulin use, also some clinical trials [12, 13]
reported about the combination therapy about sitagliptin
and insulin. The patients in the present study had
chronic diabetes mellitus, and many had already been
inadequately controlled with antidiabetic drugs and add-
itionally received sitagliptin. This suggests that the con-
ditions under which this study was conducted were
closer to routine clinical practice than those of another
Japanese dose-finding study for sitagliptin [9]. Our study
showed favorable, significant results for patients taking
sitagliptin, which were similar to those obtained in other
studies, despite the differences in study conditions.
In the present study, no significant difference in the
change in HbA1c level was observed between the groups
of patients who received different concomitant drugs.
However, the extent of the improvement was greater in
the patients with a higher baseline HbA1c level [S3].
This suggests the need to correct for the effect of the
baseline HbA1c level when interpreting data obtained in
studies with widely scattered baseline HbA1c values.
Sitagliptin-induced improvement in the HbA1c level was
more difficult to achieve in the medium-dose glimepir-
ide group than in the other groups, based on the ex-
ploratory study on the factors that affect the blood
glucose-lowering effect of sitagliptin, the multiple regres-
sion analysis of the correlation between the baseline
HbA1c level and the change in HbA1c level from base-
line based on the deviation from the approximate linear
correlation (Table 3). The baseline HbA1c level in the
medium-dose glimepiride group was high (8.24%), but
the sitagliptin-induced improvement in HbA1c level
failed to meet the expectation that the higher the base-
line HbA1c level, the greater the improvement [14, 15].
Although there is no report stating that Glimepiride is
likely to cause the secondary failure, in comparison with
Sulfonylurea, Biguanide and Thiazolidinedione, it is re-
ported that Sulfonylurea causes the secondary failure [2].
Although Glimepiride doesn’t beget the secondary fail-
ure easily in Sulfonylurea [16], compared to other drug
groups in this study, it is also presumed that in Glime-
piride middle-dose group, the pancreas may become
exhausted. We can’t identify the cause of it because
there were some patients who didn’t laboratory test.
Fig. 3 ΔHbA1c level according to concomitant drug type (3 months)
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However the duration of Glimepiride middle-dose group
was 10.2 years, it was longer than overall. Consequently,
the effect of sitagliptin might not be obtained easily. By
contrast, in a study where glimepiride was administered
at a low or high dose and sitagliptin was added after
dose reduction of glimepiride [17], sufficient efficacy was
achieved in both groups. Patients in actual clinical set-
tings have diverse treatment histories, which requires fu-
ture studies on sitagliptin co-administration with
medium- or high-dose glimepiride. Although, smoking
and drinking rate are both high in the medium-dose gli-
mepiride group. But we judged it is not significant ele-
ments in the multiple regression analysis.
To prevent complications, the target HbA1c level is
<7.0% (53 mmol/mol) and the target fasting blood glu-
cose level is 130 mg/dL for blood glucose control [6]. In
the present study, the rate of achieving the target control
level improved for both HbA1c and fasting blood glu-
cose levels.
Laboratory test results showed that the homeostatic
model of assessment (β index) significantly increased at
3 month after starting treatment compared with its base-
line value, suggesting that sitagliptin enhances insulin
secretion.
Patients with type 2 diabetes mellitus have reduced num-
bers of pancreatic β cells [18, 19]. In an animal experiment,
sitagliptin reportedly had pancreatic β cell-protecting and
growth-promoting effects [20], in our present study, the C-
peptide reactivity index (CPI) significantly increased at
3 months after starting treatment. It was more likely be-
cause of improved beta-cell function rather than increased
beta-cell mass because it was just 3 months after the start
Table 2 Laboratory test results
Parameter n 0 month
(mean ± SE)
n 3 months (mean ± SE)
Δ3 months, mean (95% CI)
p n 12 months (mean ± SE)
Δ12 months, mean (95% CI)
p
HbA1c 649 7.86 ± 0.04 635
634
7.12 ± 0.04
−0.73 (−0.80, −0.67)
0.001> 577
576
7.11 ± 0.04
−0.69 (−0.76, −0.62)
0.001>
Converted mean HbA1c(mmol/mol) 62 54 54
Fasting blood glucose 493 159.2 ± 1.9 446
413
135.1 ± 1.6
−26.3 (−29.7, −22.9)
0.001> 394
361
135.9 ± 1.7
−23.2 (−27.3, −19.2)
0.001>
HOMA-R 384 2.83 ± 0.09 367
318
2.71 ± 0.14
−0.36 (−0.51, −0.22)
0.001> 331
275
2.66 ± 0.11
−0.29 (−0.47, −0.10)
0.002
HOMA-β 382 32.1 ± 1.4 364
315
47 ± 3.2
11.5 (8.4, 14.6)
0.001> 324
270
43.9 ± 2
11.1 (7.6, 14.6)
0.001>
Fasting insulin 384 7.22 ± 0.21 367
318
8.09 ± 0.43
0.21 (−0.15, 0.57)
0.254 331
275
7.77 ± 0.29
0.29 (−0.10, 0.67)
0.147
1.5AG 254 6.4 ± 0.3 248
240
11.3 ± 0.4
4.8 (4.3, 5.2)
0.001> 213
207
10.2 ± 0.4
3.8 (3.2, 4.3)
0.001>
Glycoalbumin 254 21.1 ± 0.2 248
240
18.2 ± 0.2
−2.7 (−3.1, −2.4)
0.001> 213
207
18.5 ± 0.2
−2.5 (−2.9, −2.2)
0.001>
C-Peptide 200 2.1 ± 0.06 197
177
2.07 ± 0.06
0 (−0.11, 0.1)
0.925 152
137
2.17 ± 0.08
0.05 (−0.06, 0.15)
0.380
Proinsulin-to-insulin ratio 193 0.51 ± 0.02 187
169
0.45 ± 0.02
−0.05 (−0.08, −0.02)
0.033 150
135
0.49 ± 0.02
−0.01 (−0.05, 0.03)
0.857
CPI 200 1.38 ± 0.05 197
177
1.56 ± 0.05
0.23 (0.15, 0.32)
0.001> 152
137
1.66 ± 0.07
0.28 (0.18, 0.38)
0.001>
SBP 646 130.9 ± 0.6 635
634
129.3 ± 0.6
−1.7 (−2.9, −0.6)
0.004 576
575
130.2 ± 0.6
−0.3 (−1.6, 0.9)
0.587
DBP 646 76.5 ± 0.4 635
634
75.3 ± 0.4
−1.2 (−1.9, −0.4)
0.003 576
575
75.6 ± 0.4
−0.9 (−1.7, −0.1)
0.022
BMI 630 25.19 ± 0.17 601
599
25.24 ± 0.17
0 (−0.10, 0.05)
0.987 552
549
25.1 ± 0.18
−0.08 (−0.20, 0)
0.064
Triglycerides 589 149.3 ± 4.1 569
551
146.7 ± 5.1
−6.1 (−13.0, 0.7)
0.081 537
517
142.5 ± 4.2
−8.9 (−16.0, −1.3)
0.021
HDL-C 574 55 ± 0.6 555
537
53.8 ± 0.6
−1.1 (−1.8, −0.5)
0.001 527
506
53.6 ± 0.6
−1.6 (−2.3, −0.9)
0.001>
LDL-C 589 113.9 ± 1.2 563
545
110 ± 1.2
−3.2 (−4.9, −1.5)
0.001> 533
512
110.3 ± 1.2
−3.4 (−5.6, −1.2)
0.003
Upper row: Observed value (mean ± SE)
Lower row: Change (mean [95% CI])
p-value: versus 0 month, paired t-test
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of sitagliptin, and considering this was an observation in
human subjects. However, Nishimura et al. reported that
CPI increased from baseline to 3, 6, 12, 18, and 24 months
after the start of sitagliptin administration [21]. This indi-
cated the pancreatic β cell-protective effect of sitagliptin in
a clinical setting. Nishimura et al.also reported that greater
CPI increase after sitagliptin administration were associated
with the response to sitagliptin [21]. In our study, the num-
ber of patients who test CPI was limited. So we didn’t ana-
lysis CPI as the elements of logistic analysis. But CPI may
be benchmark of the efficacy of Sitagliptin.
However, the insulin secretion-enhancing effect of
glucagon-like peptide 1 is reportedly dependent on the
blood glucose level [22]. A meta-analysis on the effect of
DPP-4 inhibitors revealed that the hypoglycemic risk
from DPP-4 inhibitors is similar to that from placebo or
thiazolidines but lower than that from sulfonylurea drugs
[23]. Sitagliptin did not induce excessive hypoglycemia
[10], and in the present study, mild hypoglycemia oc-
curred in only three patients.
DPP-4 inhibitors do not induce body weight increases
[8, 24–26]. In the present study, sitagliptin did not cause
any increase in the body mass index. Sitagliptin also de-
creases postprandial triglyceride level [27] and lowers
blood pressure, blood lipid level [28] and alkaline phos-
phatase level [29]. Our present study also showed de-
creased systolic and diastolic blood pressures, decreased
LDL-C level and decreased triglyceride levels, which is
similar to results from previously published studies.
Incretin is secreted from the gastrointestinal tract by
the stimulation of molecules such as glucose and fats
that are produced after food is taken into the digestive
organs. Thus, incretin enhances insulin secretion from
the pancreatic β cells when the blood glucose level in-
creases after a meal. By contrast, sitagliptin decreased
both postprandial and fasting blood glucose levels [26].
In the present study, sitagliptin improved fasting blood
glucose levels and the rate of achieving the target con-
trol level. Talk about adherence, Walker et al. reported
22% of DM patients are defined as poor adherence of
Table 3 Single and multiple regression analyses of baseline HbA1c and ΔHbA1c levels (at 3 months) using the deviation from the
approximate linear correlation coefficient as the dependent variable
Single regression analysis Multiple regression analysis
Independent variable Regression
coefficient
Lower Upper P-value Partial
regression
coefficient
Lower Upper P-value
Limit Limit Limit Limit
Age 0.006 0.002 0.011 0.008‡ 0.004 −0.001 0.009 0.149
Sex (male) −0.022 −0.140 0.096 0.715
Smoking habit 0.015 −0.121 0.151 0.83
Drinking habit −0.037 −0.152 0.078 0.523
Duration of diabetes mellitus −0.004 −0.012 0.005 0.377
Body mass index −0.015 −0.028 −0.001 0.029‡ −0.009 −0.023 0.005 0.207
Mean blood pressure −0.008 −0.013 −0.002 0.005‡ −0.004 −0.008 0.001 0.095
Diet/exercise group 0.097 −0.027 0.22 0.126
Low-dose glimepiride group 0.054 −0.124 0.232 0.555
Medium-dose glimepiride group −0.264 −0.472 −0.056 0.013‡ −0.249 −0.452 −0.045 0.017§
Biguanide group −0.073 −0.228 0.081 0.351
Thiazolidine group 0.082 −0.159 0.323 0.504
αGI group 0.028 −0.308 0.364 0.871
Multi-drug coadministration group −0.008 −0.131 0.115 0.9
‡p < 0.05, single regression analysis
§p < 0.05, multiple regression analysis
Table 4 Changes in antidiabetic medication during the study (After 3 months of follow-up) n = 585
Agent Sulfonylurea Biguanide Thiazolidinedione α-Glucosidase inhibitors Sitagliptin
Patients who received additional antidiabetic agent(s) 26 18 9 2 0
Patients who increased dosage 8 26 0 0 86
Patients who decreased dosage 7 4 0 0 2
Patients who stopped receiving agent(s) 8 3 20 0 0
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medicine [30], but our study showed only 5.7% of poor
adherence of sitagliptin.
We designed this study period because Iwamoto et al.
reported that clinical treatment with sitagliptin for
12 weeks provided significant and clinically meaningful re-
ductions in HbA1c. Although, if study drug doesn’t work
enough, to fix medication for a long time is not good for
patients. On the other hand, Nishimura et al. reported
that a patient’s HbA1c change at 3 months may be a
predictor of their HbA1c change at 24 months [11]. And
our study also showed the HbA1c level of 12 month was
similar to 3 month. According to the result of this study,
we assume that 3 months of observation period is not too
short to evaluate the clinical effects of sitagliptin.
Study limitations
This was an open-label observational study (patients
were not allocated to the groups), the number of pa-
tients were different in the each groups because we cate-
gorized by the type of pre-existing therapy for type 2
diabetes. In this study, we excluded participants under-
going insulin use and rapid-acting insulin secretagogues.
Dose increases of sitagliptin, and additional administra-
tion, dose changes or discontinuation of other antidia-
betic drugs were allowed starting after 3 months of
treatment. This short duration is a limitations to asses-
sing the long-term usefulness of sitagliptin administra-
tion. However, this study is significant in that it
evaluated sitagliptin efficacy in patients treated with dif-
ferent concomitant drugs in actual clinical settings.
Conclusion
Sitagliptin administration improved the HbA1c level and
the rate of achieving the target control levels in patients
with type 2 diabetes mellitus who were previously un-
treated with, or who were poorly responsive to, existing
antidiabetic drugs. Thus, sitagliptin is expected to be ef-
fective for this patient group. Concomitant administration
of sitagliptin to patients treated with medium-dose glime-
piride only slightly improved blood glucose control after
correction for the baseline HbA1c level.
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